%20--%3E%3Cmetadata%20xmlns%3Ardf%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2F02%2F22-rdf-syntax-ns%23%22%20xmlns%3Axsi%3D%22http%3A%2F%2Fwww.w3.org%2F2001%2FXMLSchema-instance%22%20xmlns%3Adc%3D%22http%3A%2F%2Fpurl.org%2Fdc%2Felements%2F1.1%2F%22%20xmlns%3Adcterms%3D%22http%3A%2F%2Fpurl.org%2Fdc%2Fterms%2F%22%3E%3Crdf%3ARDF%3E%3Crdf%3ADescription%3E%3Cdc%3Atitle%3EShadows%3C%2Fdc%3Atitle%3E%3Cdc%3Acreator%3EDiceBear%3C%2Fdc%3Acreator%3E%3Cdc%3Asource%20xsi%3Atype%3D%22dcterms%3AURI%22%3Ehttps%3A%2F%2Fwww.dicebear.com%3C%2Fdc%3Asource%3E%3Cdcterms%3Alicense%20xsi%3Atype%3D%22dcterms%3AURI%22%3Ehttps%3A%2F%2Fcreativecommons.org%2Fpublicdomain%2Fzero%2F1.0%2F%3C%2Fdcterms%3Alicense%3E%3Cdc%3Arights%3E%E2%80%9CShadows%E2%80%9D%20(https%3A%2F%2Fwww.dicebear.com)%20by%20%E2%80%9CDiceBear%E2%80%9D%2C%20licensed%20under%20%E2%80%9CCC0%201.0%E2%80%9D%20(https%3A%2F%2Fcreativecommons.org%2Fpublicdomain%2Fzero%2F1.0%2F)%3C%2Fdc%3Arights%3E%3C%2Frdf%3ADescription%3E%3C%2Frdf%3ARDF%3E%3C%2Fmetadata%3E%3Cdefs%3E%3Cg%20id%3D%22shoulders-round-a0cd8dcf%22%3E%3Cellipse%20cx%3D%2239%22%20cy%3D%2241%22%20rx%3D%2232%22%20ry%3D%2241%22%20fill%3D%22%237b373f%22%2F%3E%3C%2Fg%3E%3Cg%20id%3D%22heads-round-a0cd8dcf%22%3E%3Ccircle%20cx%3D%2231%22%20cy%3D%2238%22%20r%3D%2219%22%20fill%3D%22%237b373f%22%2F%3E%3C%2Fg%3E%3CclipPath%20id%3D%22clip-a0cd8dcf%22%3E%3Crect%20width%3D%22100%22%20height%3D%22100%22%20rx%3D%220%22%20ry%3D%220%22%2F%3E%3C%2FclipPath%3E%3C%2Fdefs%3E%3Cg%20clip-path%3D%22url(%23clip-a0cd8dcf)%22%3E%3Crect%20width%3D%22100%22%20height%3D%22100%22%20fill%3D%22%23d6eddf%22%2F%3E%3Cuse%20transform%3D%22translate(11%2051)%22%20href%3D%22%23shoulders-round-a0cd8dcf%22%2F%3E%3Cuse%20transform%3D%22translate(19%201)%22%20href%3D%22%23heads-round-a0cd8dcf%22%2F%3E%3C%2Fg%3E%3C%2Fsvg%3E)
AstraZeneca investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol
bloom.bgAstraZeneca Investors See Little Logic in Bristol Tie-UpAstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co.
4 reposts10 likes